<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387981</url>
  </required_header>
  <id_info>
    <org_study_id>ORV-1-02</org_study_id>
    <nct_id>NCT04387981</nct_id>
  </id_info>
  <brief_title>Mass Balance Study of [14C]-Orvepitant Oral Solution in Healthy Male Subjects</brief_title>
  <official_title>A Single Dose Study to Assess the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C] Orvepitant in Healthy Male Subjects After Oral Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerre Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerre Therapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre, open-label, non-randomised study to assess the mass balance&#xD;
      recovery, absorption, metabolism, and excretion of a single oral dose of [14C]-orvepitant in&#xD;
      healthy male subjects. It is planned to enrol 6 subjects. Each subject will receive a single&#xD;
      dose of 30 mg [14C] orvepitant containing not more than (NMT) 3.7 megabecquerel (MBq) [14C],&#xD;
      administered as an oral solution in the fasted state. Subjects will be admitted in the&#xD;
      evening on the day prior to [14C]-orvepitant administration and will be dosed in the morning&#xD;
      following an overnight fast. It is planned that subjects will remain resident in the clinical&#xD;
      unit until 168 hours post-dose (Day 8) when they will be discharged from the clinical unit.&#xD;
      Through the resident period samples (blood, urine, faeces) will be collected and analysed for&#xD;
      mass balance, total radioactivity, orvepitant levels. Metabolite profiling and ID will also&#xD;
      be performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">June 28, 2020</completion_date>
  <primary_completion_date type="Actual">June 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, single dose</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of radioactive dose recovered in urine and faeces and total percentage</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of total radioactivity in blood and plasma</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[14C]-orvepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]-orvepitant administered as 30mg single dose in oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-orvepitant</intervention_name>
    <description>Oral solution of [14C]-orvepitant</description>
    <arm_group_label>[14C]-orvepitant</arm_group_label>
    <other_name>orvepitant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males&#xD;
&#xD;
          -  Aged 30 to 65 years inclusive at the time of signing informed consent.&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.&#xD;
&#xD;
          -  Must provide written informed consent.&#xD;
&#xD;
          -  Must agree to adhere to the contraception requirements&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years.&#xD;
&#xD;
          -  Regular alcohol consumption &gt;21 units per week.&#xD;
&#xD;
          -  Current smokers and those who have smoked within the last 12 months.&#xD;
&#xD;
          -  Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 months or 10 mSv in the last 5 years.&#xD;
&#xD;
          -  Clinically significant abnormal clinical chemistry, haematology, or urinalysis as&#xD;
             judged by the Investigator.&#xD;
&#xD;
          -  Subjects with a presence of any of the following at screening: bilirubin, alanine&#xD;
             aminotransferase (ALT), or aspartate aminotransferase (AST) &gt;1.5 Ã— the upper limit of&#xD;
             normal.&#xD;
&#xD;
          -  Confirmed positive drugs of abuse test result.&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results.&#xD;
&#xD;
          -  Evidence of renal impairment at screening, as indicated by an estimated creatinine&#xD;
             clearance (CLcr) of &lt;80 mL/min using the Cockcroft-Gault equation.&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory,&#xD;
             or GI disease, neurological or psychiatric disorder, as judged by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

